Can adding RNA sequencing to germline genetic testing improve accuracy and clinical sensitivity over time compared to DNA sequencing alone?

→ Bay­er is re­fin­ing Se­bas­t­ian Guth’s role on June 30, nam­ing him se­nior Bay­er rep­re­sen­ta­tive and pres­i­dent of Bay­er US. Guth had led phar­ma­ceu­ti­cals op­er­a­tions

AstraZeneca has found success with EGFR-targeting therapies, with Tagrisso (osimertinib), a kinase inhibitor of EGFR, generating approximately $5.8bn in sales last year. Image Credit: Petronelka